Company intelligence / Profile preview

Orexia Therapeutics

London, United Kingdom

Ownership: Private
Development stage: Other

Overview

Orexia developed oral and intranasal OX2R agonists using structure-based design. Its main asset, now advanced by Centessa Pharmaceuticals as ORX142, is in Phase 2, focusing on disorders related to orexin neuron loss such as narcolepsy type 1. First clinical trials in acutely sleep-deprived healthy volunteers planned for 2025[1][3][4].

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Sosei HeptaresMedicxiX-Chem

Beyond the preview

Go deeper on Orexia Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orexia Therapeutics.

Explore the full profile